Presentation given at Health Chalenges Congress 2016. International Congress Centre, Katowcie, Poland

1. INNOVATIVE MEDICINE INITIATIVE 2
Presentation by Kazik Anhalt
Gateopen Innovation Management

2. HORIZON 2020
Health, Demographic Change and Wellbeing:
 improve our understanding of the causes and mechanisms underlying health,
healthy ageing and disease;
 improve our ability to monitor health and to prevent, detect, treat and manage
disease;
 support older persons to remain active and healthy;
test and demonstrate new models and tools for health and care delivery;
Budget in total: 7 471,8 bln EUR

3. PUBLIC- PRIVATE PARTNERSHIP
 Legal base:
Article 187TfEU
,,The Union may set up joint undertakings or any other structure necessary for the efficient execution of
Union research, technological development and demonstration programmes”
 Structure:
European Commission (EC) and pharmaceutical industry European Federation of Pharmaceutical
Industries Federation (EFPIA)
 Finance:
Horizon 2020 and private contribution in kind; €3.3 bilion in total for the period 2014-2024
EC @ €1.638 bln EUR + EFPIA @ €1.425 bln EUR + life science assocciations & Associates @ €213 mln

4. EFPIA

5. STRATEGIC RESEARCH AGENDA 2014-2024
Four major axes of research:
 target validation and biomarker research (efficacy and safety);
 adoption of innovative clinical trial paradigms;
 innovative medicines;
 patient-tailored adherence programmes

6. THE PRIORITIES (12)
• respiratory diseases;
• immune-mediated diseases;
• ageing-associated diseases;
• cancer;
• rare/orphan diseases;
• vaccines.
• antimicrobial resistance;
• osteoarthritis;
• cardiovascular diseases;
• diabetes;
• neurodegenerative diseases;
• psychiatric diseases;

7. GOVERNANCE STRUCTURE
European Commission (5) EFPIA (5) Assocciated Partner (0)
Governing Board (10)
States Representative Group
(SRG)
Strategic
opinions
Executive Director
(ExD)
Programme Office
(PO)
ScientificCommitte
(SC)
11 + 3 ad hoc
Scientific advise
Nominate 3 SC Members
Report

8. IMI DO’S
 H2020Work Programme 2016- 2017 influence
 ,,Internal’’ H2020 RDI projects with largest actors within the health
sector
 SME’s networking within consortia
 Open Innovation (cooperation and knowledge sharing)
 Open new commercial possibilities based on new services and
products
 SME 100% financing
 Provide research infrastructure
 Assisst start-ups with potential to develop

9. NATIONAL SMART SPECIALIZATIONS (KIS)
 KIS 1. Medical engeenering technologies and biomedicine
 KIS 2. Diagnostics and civilization related diseases therapy and personalized medicine
 KIS 3. Paramedical products (health lifestyle and beauty)
Purpose:
Only projects related to KIS are to be qualified for NCBiR financial support

10. PROGRAMMES SYNERGY
EU Innitiatives and
Programmes
(IMI2, EIT, H2020)
NCBiR Programmes
(InnoMed, StrategMed)
Regional Operation
Programmes (RPO)
Cross- financing and
financing vehicles for
EU level accession
?National
Smart
Specialization

11. INNOVATION HEALTH ECOSYSTEM
-POTENTIAL SYNERGY-
National Centre for Research and Development (NCBiR) strategic programme
StrategMed & InnoMed
Polish Agency for Enterprise and Development (PARP) 2.3.3 axe for
internationalization of national key clusters
Regional Operational Programme
 9.2.3 RPO WŚ Increase of access to health related services in Region
 8.3 (Enhancement of access to prevention, diagnostics and rehabilitation that
facilitate stable employment and return to work
 Działanie 1.2 (RDI in SME)

12. NCBIR STRATEGMED III CALL
Topics:
Cardiology and cardiosurgery
Oncology
Budget allocation: 115 mln PLN
Type of innitiatve: up- bottom (government driven)
Internationalization of innovation: Influence index S1W1 (increase of
participation in Horizon 2020); S2W1 (increase of grant aborption @ H2020
or ERC); S3W1
Neurology and senses
Regenerative medicine

13. VOICE FROM POLAND
,,Research priorities of IMI2 are simultaneously aligned to tose ofWHO and concern
plethora of challenges- too large and perplexed that one company, one university
or even one country could cope with”
Polish ex-member of State Representative Group

14. VOICE FROM IMI2
,,Given the great science and technology being developed in Poland, there is no
reason why Polish teams should not be part of IMI consortia. Interested parties
should find out who is applying (SRG network) and try to join. Also for SMEs - they
are eligible for 100 per cent funding in IMI 2”
Especially for Medinvest Scanner:
Pierre Meulien
Executive Director of IMI2

15. THANKS FORYOUR ATTENTION
Innovate creation, create innovation!
Kazik_Anhalt@yahoo.com
Contact me for more @: